NASDAQ: ALMS - Alumis Inc.

Yield per half year: -56.93%
Dividend yield: 0.00%
Sector: Healthcare

Share chart Alumis Inc.

Extended chart Simple chart
Financial Markets by TradingView

About Alumis Inc.

Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. It develops ESK-001, an allosteric tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis, systemic lupus erythematosus, and non-infectious uveitis; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor for neuroinflammatory and neurodegenerative diseases. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022.

more details
The company was incorporated in 2021 and is headquartered in South San Francisco, California.
Add to compare list
Add to watchlist
Add to portfolio
Add to notification price

IPO date 2024-06-28
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://www.alumis.com
Цена ао 4.59
Change price per day: 0% (4.57)
Change price per week: -5.77% (4.85)
Change price per month: -10.39% (5.1)
Change price per 3 month: -46.74% (8.58)
Change price per half year: -56.93% (10.61)
Change price per year: 0% (4.57)
Change price per 3 year: 0% (4.57)
Change price per 5 year: 0% (4.57)
Change price per 10 year: 0% (4.57)
Change price per year to date: -45.4% (8.37)
All parameters

Underestimation

Title Value Grade
P/S 0 0
P/BV 0 0
P/E 0 0
EV/EBITDA 0.0862 10
Total: 3.75

Efficiency

Title Value Grade
ROA, % -172.96 0
ROE, % -429.22 0
Total: 0

Dividends

Title Value Grade
Div yield, % 0 0
DSI 0 0
Total: 0

Debt

Title Value Grade
Debt/EBITDA -0.2077 10
Total: 10

Growth impulse

Title Value Grade
Yield Revenue, % 0 0
Yield Ebitda, % 38.11 5
Yield EPS, % -79.97 0
Total: 2.8
More

ETFShare, %Profitability for 1 year, %Dividends, %
iShares Micro-Cap ETF 0.03459 17.09 1.54048
iShares Russell 2000 Growth ETF 0.00556 38.04 0.6026
0.0227.571.07



Head Job title Payment Year of birth
Mr. Martin Babler Ph.D. President, CEO & Chairman 1965 (60 years)
Dr. David M. Goldstein Ph.D. Chief Scientific Officer 1966 (59 years)
Mr. Roy C. Hardiman J.D. Chief Business & Legal Officer 1960 (65 years)
Mr. John R. Schroer C.F.A. Chief Financial Officer 1965 (60 years)
Mr. Derrick Richardson Senior VP and Head of People & Culture 1970 (55 years)
Dr. Kenneth A. Brameld Ph.D. Head of Discovery & Esker Fellow 1973 (52 years)
Ms. Claire Langrish Ph.D. Senior VP & Head of Immunology and Translational Science
Mr. Philip Nunn Ph.D. Senior VP of Pharmacology & Project Team Leader
Dr. Jorn Drappa M.D., Ph.D. Chief Medical Officer & Head of Research and Development 1965 (60 years)
Dr. Roman G. Rubio M.D. Senior VP & Head of Clinical Development & Translational Medicine 1971 (54 years)

Address: United States, South San Francisco, 280 East Grand Avenue - open in Google maps, open in Yandex maps
Website: https://www.alumis.com